In the joint development of Sekisui Medical with the National Cancer Institute, the time for measurement is aimed at just 10 to 15 minutes, being much shorter than in existing equipment. It aims to analyze quickly CpG islands related to renal, gastric cancer or colon cancer. In Sekisui Medical, other types of cancer epigenetics are also investigated. Commercialization is expected in 2018.

Nikkei Biotech news release, June 17, 2015